(RTTNews.com) - Cara Therapeutics Inc. ( CARA ) announced Wednesday morning that the Independent Data Monitoring Committee of its Phase 3 study of KORSUVA Injection has determined that no change needs to be made to the trial's enrollment target.
Cara Therapeutics has been rising sharply since the open of trade Wednesday and is now up 1.43 at $14.43. The stock has broken out to over a 1-week high.
Read the original article on RTTNews (http://www.rttnews.com/2966389/cara-therapeutics-inc-cara-is-surging-in-early-trade.aspx)
For comments and feedback: contact firstname.lastname@example.org
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.